Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

• ClinicalTrials.gov Identifier: NCT03960177
• Recruitment Status: Recruiting
• First Posted: May 22, 2019
• Last Update Posted: May 13, 2020
• Sponsor: OHSU Knight Cancer Institute
• Collaborators: National Cancer Institute (NCI); Oregon Health and Science University
• Information provided by (Responsible Party): Lara Davis, OHSU Knight Cancer Institute

Study Description

Brief Summary:

This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.

Condition or disease	Intervention/treatment	Phase
Osteosarcoma	Drug: Glucarpidase; Other: Quality-of-Life Assessment	Early Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

I. To determine the rate of completion of 4 planned high dose methotrexate (HDMTX) doses when glucarpidase is administered after each dose.

SECONDARY OBJECTIVES:

I. To assess the length of hospital stay (LOS) associated with methotrexate (MTX) clearance following administration of glucarpidase 24 hours after HDMTX.

II. To assess the LOS associated with all causes following administration of glucarpidase 24 hours after HDMTX.

III. To assess the impact of glucarpidase administration on HDMTX efficacy. IV. To assess the safety and tolerability of 4 doses of HDMTX administered with glucarpidase in an adult osteosarcoma population.

V. To assess the efficacy of glucarpidase flat dose of 1,000 units.

OUTLINE:

Patients receive standard of care HDMTX intravenously (IV) on day 1 of weeks 4, 5, 9, and 10 as part of a standard osteosarcoma chemotherapy regimen. 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes.

After completion of study treatment, patients are followed up for 32 weeks.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
• Actual Study Start Date: March 27, 2019
• Estimated Primary Completion Date: October 1, 2020
• Estimated Study Completion Date: October 1, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Supportive care (glucarpidase); Patients receive standard of care HDMTX intravenously (IV) on day 1 of weeks 4, 5, 9, and 10 as part of a standard osteosarcoma chemotherapy regimen. 24 hours after the start of each HDMTX infusion, patients also receive glucarpidase IV over 5 minutes.	Drug: Glucarpidase; Given IV; Other Names: Acetylaspartylglutamate Dipeptidase; Carboxypeptidase G2; carboxypeptidase-G2; CPDG2; CPG2; Poly(gamma-glutamic Acid) Endohydrolase; Pteroylpolygammaglutamyl Hydrolase; Voraxaze; 9074-87-7; Other: Quality-of-Life Assessment; Ancillary studies; Other Name: Quality of Life Assessment

Outcome Measures

Primary Outcome Measures :

1. Proportion of subjects completing 4 planned doses of high dose methotrexate (HDMTX) [ Time Frame: Time from first dose of HDMTX to time of last dose of HDMTX (week 10) ]
   Will be estimated with an exact 95% confidence interval (CI).

Secondary Outcome Measures :

1. Length of hospital stay (LOS) for methotrexate (MTX) clearance [ Time Frame: Date of admission for each planned MTX infusion to date of MTX < 0.1μM for each planned MTX infusion (up to 15 days) ]
2. LOS for all causes (excluding MTX-related AEs) [ Time Frame: Date of admission for each planned MTX infusion to date of discharge for each planned MTX infusion (up to 15 days) ]
3. LOS for methotrexate (MTX)-related adverse events (AEs) [ Time Frame: Date of admission for each planned MTX infusion to date of discharge for each planned MTX infusion (up to 15 days) ]
4. Percent treatment effect at resection [ Time Frame: From start of surgery until end of surgery ]
   Defined as an admixture of degenerating wispy osteoid matrix with empty lacunae, necrotic ghost cells, and edematous stroma with loose fibrous tissue. Dense fibrosis or hyalinization or sheets of sclerotic acellular osteoid may also be present. These features are quantified by estimating the percentage of each parameter in each tumor slide and calculating the mean based on the total number of tumor slides examined. The percentage of tumor necrosis or treatment effect will be recorded from each participant's surgical pathology report.
5. Incidence of glucarpidase hypersensitivity [ Time Frame: From first dose of glucarpidase until 30 days after last dose of glucarpidase ]
   Will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.
6. Incidence of glucarpidase neutralizing antibodies [ Time Frame: From first dose of glucarpidase to 30 days after last dose of glucarpidase ]
   Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.
7. Incidence and severity of MTX-related toxicities [ Time Frame: From start of first planned MTX infusion to 30 days after last dose of glucarpidase ]
   Will be assessed according to CTCAE v 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.
8. Incidence and severity of glucarpidase toxicities [ Time Frame: From first dose of glucarpidase to 30 days after last dose of glucarpidase ]
   Will be assessed according to CTCAE v 5.0. Will be determined for participants that received at least 1 dose of glucarpidase following an HDMTX infusion. The 95% CI will be reported with the point estimate of toxicity rate.
9. MTX and DAMPA serum concentration (umol/L) at 4, 24, 24.5, 36, 48 and every 24 hours after the start of MTX infusion [ Time Frame: From start of each planned MTX infusion to time when MTX =< 0.1 uM (for each planned MTX infusion) (up to 15 days) ]
10. Proportion of glucarpidase doses (flat dose of 1000 units) that result in MTX serum concentration reduction of >= 97% from hour 24 to hour 24.5 [ Time Frame: From first dose of glucarpidase to end of study treatment (week 10) ]
    Will be presented along with 95% confidence intervals.
11. Proportion of glucarpidase doses (flat dose of 1000 units) that result in 48 hour serum MTX level < 1 uM [ Time Frame: From first dose of glucarpidase to end of study treatment (week 10) ]
    Will be presented along with 95% confidence intervals.

Eligibility Criteria

• Ages Eligible for Study: 25 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• All races and ethnic groups will be eligible

  • A minimum of 6 individuals aged >= 40 years will be enrolled. These participants are considered high-risk.
• Eastern Cooperative Oncology Group (ECOG) performance score 0-2.
• Participants must have pathologically confirmed diagnosis of osteosarcoma. Participants must be newly diagnosed and previously untreated, although initiation of doxorubicin/cisplatin prior to enrollment is permitted.
• Participants must have a recommended treatment plan for their osteosarcoma that includes planned MTX treatment at 8-12 g/m^2.
• Absolute neutrophil count (ANC) >= 1,000/mm^3 (or >= 1.0 x 10^9/L).
• Platelet count 75,000/mm^3 (or >= 75 x 10^9/L).
• Hemoglobin >= 8 g/dL.
• Serum creatinine =< 1.5 x the upper limit of normal (ULN), or glomerular filtration rate (GFR) >= 60 ml/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) formula.
• Total serum bilirubin =< 2 x ULN.
• Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) =< 2.5 x ULN.
• Participants must be willing to use appropriate contraception for the duration of study treatment and four months after completing HDMTX therapy.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Malignant disease, other than those being treated in this study. Exceptions to this exclusion include the following:

  • Malignancies that were treated curatively and have not recurred within 2 years after completion of treatment;
  • Completely resected basal cell and squamous cell skin cancers;
  • Any malignancy considered to be indolent and that has never required therapy;
  • Completely resected carcinoma in situ of any type.
• Participants with rapidly progressive disease or organ dysfunction that would prevent them from receiving planned HDMTX treatment regimen.
• Previous MTX treatment at doses >= 3 g/m^2.
• Previous treatment with glucarpidase.
• Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis. Patients who have completed curative therapy for HCV are eligible. Patients with known history of human immunodeficiency virus (HIV) infection are eligible.
• Participants with a history of hypersensitivity reactions to study agent or its excipients.
• Participants with a history of hypersensitivity to Escherichia (E).coli-derived proteins.
• Participants with large pleural or ascitic fluid collection.
• Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
• Uncontrolled intercurrent illness, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
• Unable or unwilling to discontinue use of agents that interact significantly with methotrexate metabolism or excretion.

Contacts and Locations

Locations

United States, Florida

Mayo Clinic in Florida; Recruiting

Jacksonville, Florida, United States, 32224-9980

Contact: Steven Attia 904-953-7290 Attia.Steven@mayo.edu

Principal Investigator: Steven Attia

United States, Minnesota

Mayo Clinic; Recruiting

Rochester, Minnesota, United States, 55905

Contact: Brittany Siontis 507-293-0585 Siontis.Brittany@mayo.edu

Principal Investigator: Brittany Siontis

United States, Oregon

OHSU Knight Cancer Institute; Recruiting

Portland, Oregon, United States, 97239

Contact: Lara E. Davis 503-494-8423 davisla@ohsu.edu

Principal Investigator: Lara E. Davis

Sponsors and Collaborators

OHSU Knight Cancer Institute

National Cancer Institute (NCI)

Oregon Health and Science University

Investigators

• Principal Investigator: Lara E Davis; OHSU Knight Cancer Institute

More Information

• Responsible Party: Lara Davis, Principal Investigator, OHSU Knight Cancer Institute
• ClinicalTrials.gov Identifier: NCT03960177
• Other Study ID Numbers: STUDY00019380; NCI-2019-02257 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); STUDY00019380 ( Other Identifier: OHSU Knight Cancer Institute ); P30CA069533 ( U.S. NIH Grant/Contract )
• First Posted: May 22, 2019
• Last Update Posted: May 13, 2020
• Last Verified: May 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Osteosarcoma; Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma